Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells $299,200.00 in Stock

Posted by George Bondi on May 22nd, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) insider Wim Souverijns sold 10,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $29.92, for a total value of $299,200.00. Following the transaction, the insider owned 45,111 shares in the company, valued at approximately $1,349,721.12. This trade represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Pharvaris Trading Up 3.7%

Shares of NASDAQ:PHVS opened at $30.54 on Friday. The stock’s fifty day simple moving average is $28.41 and its two-hundred day simple moving average is $26.79. Pharvaris N.V. has a 1-year low of $15.46 and a 1-year high of $33.33. The stock has a market cap of $2.00 billion, a PE ratio of -9.60 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, sell-side analysts forecast that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Several large investors have recently added to or reduced their stakes in the company. Stempoint Capital LP increased its holdings in Pharvaris by 48.4% in the 1st quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock worth $2,447,000 after acquiring an additional 28,248 shares during the last quarter. ADAR1 Capital Management LLC increased its holdings in Pharvaris by 23.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock worth $2,981,000 after acquiring an additional 20,000 shares during the last quarter. Amundi increased its holdings in Pharvaris by 12.0% in the 1st quarter. Amundi now owns 30,952 shares of the company’s stock worth $874,000 after acquiring an additional 3,312 shares during the last quarter. Rock Springs Capital Management LP increased its holdings in Pharvaris by 3.6% in the 1st quarter. Rock Springs Capital Management LP now owns 645,533 shares of the company’s stock worth $18,236,000 after acquiring an additional 22,131 shares during the last quarter. Finally, SummitTX Capital L.P. increased its holdings in Pharvaris by 27.7% in the 1st quarter. SummitTX Capital L.P. now owns 29,184 shares of the company’s stock worth $824,000 after acquiring an additional 6,325 shares during the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on PHVS shares. Wedbush raised their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, April 7th. Royal Bank Of Canada dropped their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Finally, UBS Group set a $74.00 target price on Pharvaris in a research report on Wednesday, May 13th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

View Our Latest Analysis on Pharvaris

Pharvaris Company Profile

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.